Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Fei Ye, Ph.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Nebhan CA, Cortellini A, Ma W, Ganta T, Song H, Ye F, Irlmeier R, Debnath N, Saeed A, Radford M, Alahmadi A, Diamond A, Hoimes C, Ramaiya N, Presley CJ, Owen DH, Abou Alaiwi S, Nassar A, Ricciuti B, Lamberti G, Bersanelli M, Casartelli C, Buti S, Marchetti P, Giusti R, Filetti M, Vanella V, Mallardo D, Macherla S, Sussman TA, Botticelli A, Galetta D, Catino A, Pizzutilo P, Genova C, Dal Bello MG, Kalofonou F, Daniels E, Ascierto PA, Pinato DJ, Choueiri TK, Johnson DB, Marron TU, Wang Y, Naqash AR. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. JAMA Oncol. 2021 Dec 01; 7(12):1856-1861. PMID: 34734989; PMCID: PMC8569601.
    Citations: 4     Fields:    Translation:Humans
  2. Halle BR, Betof Warner A, Zaman FY, Haydon A, Bhave P, Dewan AK, Ye F, Irlmeier R, Mehta P, Kurtansky NR, Lacouture ME, Hassel JC, Choi JS, Sosman JA, Chandra S, Otto TS, Sullivan R, Mooradian MJ, Chen ST, Dimitriou F, Long G, Carlino M, Menzies A, Johnson DB, Rotemberg VM. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. J Immunother Cancer. 2021 10; 9(10). PMID: 34635495; PMCID: PMC8506877.
    Citations: 3     Fields:    Translation:Humans
  3. Johnson DB, Patrinely JR, Ye F. Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events-Reply. JAMA Oncol. 2021 10 01; 7(10):1574-1575. PMID: 34383022.
    Citations:    Fields:    Translation:Humans
  4. Patrinely JR, Johnson R, Lawless AR, Bhave P, Sawyers A, Dimitrova M, Yeoh HL, Palmeri M, Ye F, Fan R, Davis EJ, Rapisuwon S, Long GV, Haydon A, Osman I, Mehnert JM, Carlino MS, Sullivan RJ, Menzies AM, Johnson DB. Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. JAMA Oncol. 2021 05 01; 7(5):744-748. PMID: 33764387; PMCID: PMC7995124.
    Citations: 25     Fields:    Translation:Humans
  5. Shah KP, Song H, Ye F, Johnson DB. Prognostic Clinical and Radiographic Biomarkers for BRAF-Targeted Therapy in Advanced Melanoma. Oncologist. 2021 02; 26(2):e333-e335. PMID: 33044751; PMCID: PMC7873326.
    Citations: 1     Fields:    Translation:Humans
  6. Ormseth MJ, Wu Q, Zhao S, Allen RM, Solus J, Sheng Q, Guo Y, Ye F, Ramirez-Solano M, Bridges SL, Curtis JR, Vickers K, Stein CM. Circulating microbial small RNAs are altered in patients with rheumatoid arthritis. Ann Rheum Dis. 2020 12; 79(12):1557-1564. PMID: 32958509.
    Citations: 4     Fields:    Translation:Humans
  7. Young AC, Quach HT, Song H, Davis EJ, Moslehi JJ, Ye F, Williams GR, Johnson DB. Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma. J Immunother Cancer. 2020 07; 8(2). PMID: 32747470.
    Citations: 25     Fields:    Translation:Humans
  8. Patrinely JR, Young AC, Quach H, Williams GR, Ye F, Fan R, Horn L, Beckermann KE, Gillaspie EA, Sosman JA, Friedman DL, Moslehi JJ, Johnson DB. Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. Eur J Cancer. 2020 08; 135:211-220. PMID: 32599411.
    Citations: 12     Fields:    Translation:Humans
  9. Patrinely JR, Baker LX, Davis EJ, Song H, Ye F, Johnson DB. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma. Cancer. 2020 08 01; 126(15):3448-3455. PMID: 32463489.
    Citations: 6     Fields:    Translation:Humans
  10. Shah KP, Song H, Ye F, Moslehi JJ, Balko JM, Salem JE, Johnson DB. Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy. Cancer Immunol Res. 2020 07; 8(7):851-855. PMID: 32350001.
    Citations: 20     Fields:    Translation:Humans
  11. Wang DY, McQuade JL, Rai RR, Park JJ, Zhao S, Ye F, Beckermann KE, Rubinstein SM, Johnpulle R, Long GV, Carlino MS, Menzies AM, Davies MA, Johnson DB. The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. Oncologist. 2020 03; 25(3):e602-e605. PMID: 32162820.
    Citations: 18     Fields:    Translation:Humans
  12. Johnson DB, Ye F, Dewan AK. Longer Survival With Anti-Programmed Cell Death 1 and Development of Cutaneous Toxic Effects, an Expected Association-In Reply. JAMA Oncol. 2019 Nov 01; 5(11):1642-1643. PMID: 31556913.
    Citations:    Fields:    
  13. Zhou AY, Wang DY, McKee S, Ye F, Wen CC, Wallace DE, Ancell KK, Conry RM, Johnson DB. Correlates of response and outcomes with talimogene laherperpvec. J Surg Oncol. 2019 Sep; 120(3):558-564. PMID: 31264725.
    Citations: 7     Fields:    Translation:HumansCells
  14. Davis EJ, Perez MC, Ayoubi N, Zhao S, Ye F, Wang DY, Sosman JA, Al-Rohil RN, Eroglu Z, Johnson DB. Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma. J Immunother. 2019 Jul-Aug; 42(6):221-227. PMID: 30882548.
    Citations: 10     Fields:    Translation:HumansCells
  15. Quach HT, Dewan AK, Davis EJ, Ancell KK, Fan R, Ye F, Johnson DB. Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma. JAMA Oncol. 2019 Jun 01; 5(6):906-908. PMID: 30998826.
    Citations: 35     Fields:    Translation:Humans
  16. Chen DQ, Cao G, Chen H, Argyopoulos CP, Yu H, Su W, Chen L, Samuels DC, Zhuang S, Bayliss GP, Zhao S, Yu XY, Vaziri ND, Wang M, Liu D, Mao JR, Ma SX, Zhao J, Zhang Y, Shang YQ, Kang H, Ye F, Cheng XH, Li XR, Zhang L, Meng MX, Guo Y, Zhao YY. Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan. Nat Commun. 2019 04 01; 10(1):1476. PMID: 30931940.
    Citations: 69     Fields:    Translation:HumansAnimalsCells
  17. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 12 01; 4(12):1721-1728. PMID: 30242316; PMCID: PMC6440712.
    Citations: 517     Fields:    Translation:Humans
  18. Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. Oncoimmunology. 2017; 6(10):e1344805. PMID: 29123955.
    Citations: 64     Fields:    
  19. Wang DY, Eroglu Z, Ozgun A, Leger PD, Zhao S, Ye F, Luke JJ, Joseph RW, Haq R, Ott PA, Hodi FS, Sosman JA, Johnson DB, Buchbinder EI. Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. Cancer Immunol Res. 2017 05; 5(5):357-362. PMID: 28396509.
    Citations: 17     Fields:    Translation:Humans
  20. Johnson DB, Pectasides E, Feld E, Ye F, Zhao S, Johnpulle R, Merritt R, McDermott DF, Puzanov I, Lawrence D, Sosman JA, Buchbinder E, Sullivan RJ. Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. J Immunother. 2017 01; 40(1):31-35. PMID: 27846054.
    Citations: 38     Fields:    Translation:Humans
  21. Guo Y, Wu J, Zhao S, Ye F, Su Y, Clark T, Sheng Q, Lehmann B, Shu XO, Cai Q. RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Specimens for Gene Expression Quantification and Data Mining. Int J Genomics. 2016; 2016:9837310. PMID: 27774452.
    Citations: 9     
  22. Samuels DC, Wang J, Ye F, He J, Levinson RT, Sheng Q, Zhao S, Capra JA, Shyr Y, Zheng W, Guo Y. Heterozygosity Ratio, a Robust Global Genomic Measure of Autozygosity and Its Association with Height and Disease Risk. Genetics. 2016 11; 204(3):893-904. PMID: 27585849.
    Citations: 17     Fields:    Translation:Humans
  23. Shreders A, Joseph R, Peng C, Ye F, Zhao S, Puzanov I, Sosman JA, Johnson DB. Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. Cancer Immunol Res. 2016 07; 4(7):569-73. PMID: 27197063.
    Citations: 7     Fields:    Translation:Humans
  24. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol. 2016 Feb; 2(2):234-40. PMID: 26633184.
    Citations: 215     Fields:    Translation:Humans
  25. Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer. 2015 Dec; 51(18):2792-9. PMID: 26608120; PMCID: PMC4666799.
    Citations: 126     Fields:    Translation:HumansCells
  26. Guo Y, Bosompem A, Mohan S, Erdogan B, Ye F, Vickers KC, Sheng Q, Zhao S, Li CI, Su PF, Jagasia M, Strickland SA, Griffiths EA, Kim AS. Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes. BMC Genomics. 2015 Sep 24; 16:727. PMID: 26400237.
    Citations: 25     Fields:    Translation:HumansCells
  27. Johnson DB, Peng C, Abramson RG, Ye F, Zhao S, Wolchok JD, Sosman JA, Carvajal RD, Ariyan CE. Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. Oncologist. 2015 Jun; 20(6):648-52. PMID: 25964307.
    Citations: 23     Fields:    Translation:HumansCTClinical Trials
  28. Johnson DB, Friedman DL, Berry E, Decker I, Ye F, Zhao S, Morgans AK, Puzanov I, Sosman JA, Lovly CM. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. Cancer Immunol Res. 2015 May; 3(5):464-9. PMID: 25649350.
    Citations: 31     Fields:    Translation:HumansCTClinical Trials
  29. Guo Y, Zhao S, Su PF, Li CI, Ye F, Flynn CR, Shyr Y. Statistical strategies for microRNAseq batch effect reduction. Transl Cancer Res. 2014 Jun 01; 3(3):260-265. PMID: 25258704.
    Citations: 6     
  30. Guo Y, Zhao S, Ye F, Sheng Q, Shyr Y. MultiRankSeq: multiperspective approach for RNAseq differential expression analysis and quality control. Biomed Res Int. 2014; 2014:248090. PMID: 24977143.
    Citations: 41     Fields:    Translation:Humans
  31. Guo Y, Zhao S, Sheng Q, Ye F, Li J, Lehmann B, Pietenpol J, Samuels DC, Shyr Y. Multi-perspective quality control of Illumina exome sequencing data using QC3. Genomics. 2014 May-Jun; 103(5-6):323-8. PMID: 24703969.
    Citations: 48     Fields:    Translation:Humans
  32. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012 Feb 23; 366(8):707-14. PMID: 22356324; PMCID: PMC3724515.
    Citations: 845     Fields:    Translation:HumansCTClinical Trials
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Ye's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (138)
Co-Authors (15)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.